Product Information

DABIGATRAN ETEXILATE 110 MG CP is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.8695 per EA under NDC 43598045360. Its NADAC has been published 88 times since Mar 19, 2025.

FDA first approved this application on Jan 28, 2025. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

DABIGATRAN ETEXILATE 110 MG CP

Dabigatran etexilate
$0.8695per EA

Strength

110 mg/1

NDC

43598045360

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA208048

FDA Approved

1/28/2025

TE Code

AB

On Market Since

2/28/2025

Pharmacological Classes

Direct Thrombin Inhibitor
Thrombin Inhibitors

Price Statistics

The NADAC for DABIGATRAN ETEXILATE 110 MG CP has been published 88 times since Mar 19, 2025, and over the history we have for it it has declined 56.1%. The table below summarizes its recorded NADAC range and movement.

Current price$0.8695 per EA
All-time high$1.9786 (Apr 16, 2025)
All-time low$0.8695 (Nov 18, 2026)
52-week high$1.6053
52-week low$0.8695
Median price$1.3380
Average price$1.3928
Largest weekly change-12.4% (Dec 17, 2025)
Weeks tracked88
Tracking sinceMar 19, 2025

Price History

1W

-3.0%

1M

-7.3%

3M

-8.1%

6M

-5.5%

1Y

-45.8%

3Y

N/A

5Y

N/A

All

-56.1%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dabigatran etexilate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of DABIGATRAN ETEXILATE 110 MG CP?

The current National Average Drug Acquisition Cost (NADAC) for DABIGATRAN ETEXILATE 110 MG CP, manufactured by Dr. Reddy's Laboratories Inc., is $0.8695 per EA (NDC 43598045360), effective Nov 18, 2026.

How has the price of DABIGATRAN ETEXILATE 110 MG CP changed over time?

Over the history we have for it, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has declined 56.1%. It has been tracked across 88 weekly CMS publications since Mar 19, 2025.

What are the highest and lowest recorded NADAC prices for DABIGATRAN ETEXILATE 110 MG CP?

Since Mar 19, 2025, the NADAC for DABIGATRAN ETEXILATE 110 MG CP has ranged from a low of $0.8695 (Nov 18, 2026) to a high of $1.9786 (Apr 16, 2025), with a median of $1.3380 per EA.

Are there cheaper alternatives to DABIGATRAN ETEXILATE 110 MG CP?

No other NADAC-published product currently shares the active ingredient and strength of DABIGATRAN ETEXILATE 110 MG CP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures DABIGATRAN ETEXILATE 110 MG CP?

DABIGATRAN ETEXILATE 110 MG CP (NDC 43598045360) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.